Monday, Jan 22 2018 | Time 14:03 Hrs(IST)
image
  • India for principled approach to climate change
  • Prez, PM wish people on Basant Panchami
  • Nine-yr-old girl dies, two kids injured in celebratory firing in Firozabad
  • CM to present annual budget for 2018-19 tomorrow
  • SC stays proceedings in DHC, BHC on sanitary napkins case
  • Disqualifying AAP MLAs miscarriage of natural justice: Sinha
  • 32 people died of swine flu in J&K in 2017: Govt
  • Paliwal appointed Chairman of UP Subordinate Service Commission
  • Power crisis rocks J&K Assembly, Oppn stages walkout
  • Nepal: ECN publishes NA voters' list
  • Veeam Appoints Sandeep Bhambure as India Business Lead
  • Federer eases past Fucsovics into Melbourne quarter-finals
  • Bomb at pork stall in market in Thailand's south kills 3, wounds 22
  • SC to hear pleas of Raj, MP on Padmaavat on Tuesday
  • NA body summons Anwar over Naqeebullah encounter
Science Technology Share

Dengvaxia, a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Dengvaxia,  a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Kolkata, Dec 5 (UNI) There continues to be a strong public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1-4.

One dengue vaccine has been licensed, Dengvaxia (also referred to as CYD-TDV), developed by Sanofi Pasteur. Dengvaxia is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur, given as a 3-dose series on a 0/6/12 month schedule.

Dengvaxia is the first dengue vaccine to be licensed and has now been approved by 19 regulatory authorities for use in endemic areas in persons typically ranging from 9-45 (in some countries 9-60) years of age.

It has been introduced in two subnational programs in the Philippines and Brazil targeting about one million individuals. It is otherwise available on the private market in countries where there is a marketing authorization.

Dengvaxia has been evaluated in two Phase 3 clinical trials (CYD14 trial in five countries in Asia and CYD15 trial in five countries in Latin America). Together, these trials included over 30,000 participants aged 2 to 16 years.

Vaccine efficacy against confirmed dengue pooled across both trials was 59.2 per cent in the year following the primary series, and 79.1 per cent against severe dengue. Efficacy varied by serotype, by age at vaccination and serostatus at baseline (i.e., previous exposure to dengue prior to vaccination).

While efficacy was reported against hospitalized and severe dengue in Years 1 and 2 post-dose 1, an excess of cases of hospitalized and severe dengue cases in those receiving Dengvaxia was seen in Year 3 in some subgroups, although it is based on relatively small numbers of cases. Whether the increased risk was due to age or serostatus at baseline, which is highly correlated with age, could not be fully clarified with the available data at the time.

For subjects aged 9 and above, in the first 25 months of the phase 3 trials, there was a reduction in severe dengue by 93 per cent and a reduction in hospitalizations by 81 per

cent.

MORE UNI BM SJC

More News
Middle East respiratory syndrome, a viral respiratory disease

Middle East respiratory syndrome, a viral respiratory disease

19 Jan 2018 | 1:30 PM

Kolkata, Jan 19 (UNI) Middle East respiratory syndrome (MERS) is a viral respiratory disease
caused by a novel coronavirus (Middle East respiratory syndrome coronavirus, or MERSā€CoV)
that was first identified in Saudi Arabia in 2012.

 Sharesee more..

Science has to be people centric: Dr Harsh Vardhan

18 Jan 2018 | 1:08 PM

Hyderabad, Jan 18 (UNI) Union Minister for Science and Technology Harsh Vardhan has said that the Science has to be people centric and its benefits would deliver to the people.

 Sharesee more..
Greater efforts needed to meet international family planning goals

Greater efforts needed to meet international family planning goals

17 Jan 2018 | 12:32 PM

Kolkata, Jan 17 (UNI) Women and girls have a human right to choose whether and when to become pregnant.

 Sharesee more..
TN pioneer in organ transplants, other states should follow it : Venkaiah

TN pioneer in organ transplants, other states should follow it : Venkaiah

16 Jan 2018 | 5:13 PM

Chennai, Jan 16 (UNI) Observing that Tamil Nadu was a pioneering state in organ transplantation in the country, Vice President M Venkaiah Naidu on Tuesday said other states should emulate it in providing affording medical care to the people.

 Sharesee more..
Echinococcosis, a parasitic disease that occurs in two main forms in humans

Echinococcosis, a parasitic disease that occurs in two main forms in humans

13 Jan 2018 | 12:16 PM

Kolkata, Jan 13 (UNI) Echinococcosis is a parasitic disease that occurs in two main forms in humans: cystic echinococcosis (also known as hydatidosis) and alveolar echinococcosis, caused by the tapeworms Echinococcus granulosus and Echinococcus multilocularis, respectively.

 Sharesee more..
image